Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 6Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Neoplasms 2Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colonic Neoplasms 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × Endosonography × Clear all
NCT06122896 2026-05-29

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Recruiting
5,000 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02863783 2023-03-06

EUS Fiducial for Pancreas Surgery

University of Southern California

Phase NA Unknown
20 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡